No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Scott Davie Appointed TriSalus Chief Technology Officer

Editor: What To Know

  • A 25-year veteran of the medical device industry across multiple industry segments, Davie also will serve as site lead for the company's Westminster, CO facility and report to the company's President and Chief Executive Officer, Mary Szela.
  • Davie earned his Bachelor of Science in Mechanical Engineering from MIT and his Master of Science in Mechanical Engineering from Stanford with a focus on Biomechanics and Electronics.
  • Lives short, I am thrilled to be part of the TriSalus team and embrace the opportunity to dramatically improve therapeutic delivery and outcomes for these cancer patients,” said Davie.

TriSalus Life Sciences announced the appointment of Scott Davie to the role of Chief Technology Officer, deepening the company’s leadership capabilities as it builds an integrated therapeutic/drug delivery portfolio.

As chief technology officer, Scott Davie will oversee research and development of the company’s intravascular infusion systems powered by its proprietary Pressure Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology, as well as operations, pre-clinical execution, and management of the IP portfolio. A 25-year veteran of the medical device industry across multiple industry segments, Davie also will serve as site lead for the company’s Westminster, CO facility and report to the company’s President and Chief Executive Officer, Mary Szela.

“We’re thrilled to add Scott’s deep experience in medical device development and commercialization to the critical work underway at TriSalus. Our PEDD-based products have tremendous promise for treating solid tumors, and under his knowledge and leadership skills, we’re poised to help lead a transformation in cancer care,” said Szela. “Additionally, his experience in the U.S., Canadian, and Japanese markets is essential to supporting our global development efforts.”

Prior to joining TriSalus Life Sciences, Davie held a number of leadership positions at Medtronic creating and leading teams and engineering departments. He has delivered innovative, complex, therapeutic and diagnostic systems from conceptualization through market launch including implantable cardiac devices, AF ablation systems, and hospital based diagnostic platforms. His regulatory experience spans filings and registrations via 510k’s, PMA supplements, original PMAs, and CE Marks.

Davie earned his Bachelor of Science in Mechanical Engineering from MIT and his Master of Science in Mechanical Engineering from Stanford with a focus on Biomechanics and Electronics.

“As someone who’s watched cancer cut family members’ lives short, I am thrilled to be part of the TriSalus team and embrace the opportunity to dramatically improve therapeutic delivery and outcomes for these cancer patients,” said Davie.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy